$OTLK

4 theses

bullish 100%neutral 0%bearish 0%

Avg return (1m)

-18.7%

Win rate (1m)

0% (4 resolved)

1d 3d 1w 1m 3m 6m 1y

Past performance does not predict future results. Informational only, not investment advice.

Recent theses

Prices as of Sep 18, 4:30 PM ET

$OTLKSEC Form 4bullish

Sukhtian Ghiath M. · Outlook Therapeutics, Inc. · 47d agono track record yet

Long 2,525,252 shares of OTLK

Bought 2,525,252 @ $0.99 avg · $2,499,999 · 2026-08-12

Form 4: Sukhtian Ghiath M. bought OTLK

Sukhtian Ghiath M. (Director at Outlook Therapeutics, Inc.) reported an open-market purchase of 2,525,252 shares of OTLK at an average $0.99, roughly $2,499,999, in a Form 4 filed 2026-08-14.

At post $0.76Now $0.65-13.7% since postedas of Sep 18, 4:30 PM ET

1d—

3d-11.1%

1w-14.4%

1m-12.7%

3m—

6m—

1y—

View filing on SEC.gov →

$OTLKr/pennystocksꉓꍏ꓄ꍏ꒒ꌩꌗ꓄bullish

u/Avish_Golakiya · 90d ago23 prior · awaiting results

“long several of these”

5 of the 6 biotech names I posted 5 weeks ago hit their catalyst (and the 1 that hasn't)

Won Lytenava appeal via formal dispute resolution in May and FDA accepted resubmitted BLA in June. Stock more than doubled, though a registered-direct raise introduced dilution.

At post $1.45Now $0.65-55.0% since postedas of Sep 18, 4:30 PM ET

1d—

3d—

1w+15.9%

1m-32.6%

3m—

6m—

1y—

original post →

$OTLKr/pennystocksGeneral Discussionbullish

u/ImBadAtIt · 100d agono track record yet

“taking the gamble”

OTLK - ONS-5010/LYTENAVA

OTLK resubmitted its BLA to the FDA with a decision expected by end of July. Approval of ONS-5010/LYTENAVA could capture a meaningful market share, offering significant upside despite the early-stage risk profile.

At post $1.70Now $0.65-61.6% since postedas of Sep 18, 4:30 PM ET

1d-1.2%

3d+0.6%

1w-6.5%

1m-22.4%

3m—

6m—

1y—

original post →

$OTLKr/pennystocksDDbullish

u/Joehax00 · 106d ago2 prior · awaiting results

$OTLK - Outlook Therapeutics: one-drug biotech, FDA decision July 29, ~1 quarter of cash. Binary setup DD.

OTLK is a binary biotech betting on July 29, 2026 FDA approval of LYTENAVA, an injectable bevacizumab for wet AMD. The May 2026 appeal win established substantial efficacy evidence, leaving only labeling sign-off; approval would unlock a $8.5B market with 12 years of exclusivity as the sole approved on-label ophthalmic bevacizumab, while rejection with only one quarter of cash likely results in wipeout-level dilution or restructuring.

At post $1.57Now $0.65-58.4% since postedas of Sep 18, 4:30 PM ET

1d+5.1%

3d+0.6%

1w+8.3%

1m-7.0%

3m-59.4%

6m—

1y—

original post →

End of results.